ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 232 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,221,231 | -12.3% | 106,585 | +0.8% | 0.01% | 0.0% |
| Q2 2023 | $2,532,281 | +13.3% | 105,732 | -11.0% | 0.01% | 0.0% |
| Q1 2023 | $2,235,063 | +15.2% | 118,760 | -2.5% | 0.01% | +16.7% |
| Q4 2022 | $1,939,629 | -3.9% | 121,836 | -1.2% | 0.01% | 0.0% |
| Q3 2022 | $2,018,000 | +10.5% | 123,368 | -4.8% | 0.01% | +20.0% |
| Q2 2022 | $1,827,000 | -52.9% | 129,631 | -19.1% | 0.01% | -37.5% |
| Q1 2022 | $3,882,000 | +3.8% | 160,300 | 0.0% | 0.01% | +14.3% |
| Q4 2021 | $3,741,000 | +45.2% | 160,300 | +3.4% | 0.01% | +40.0% |
| Q3 2021 | $2,576,000 | -31.9% | 155,100 | 0.0% | 0.01% | -37.5% |
| Q2 2021 | $3,783,000 | +930.8% | 155,100 | +990.5% | 0.01% | +700.0% |
| Q1 2021 | $367,000 | -51.8% | 14,223 | -0.0% | 0.00% | -50.0% |
| Q4 2020 | $761,000 | +24.3% | 14,230 | -4.0% | 0.00% | 0.0% |
| Q3 2020 | $612,000 | -19.5% | 14,830 | -5.4% | 0.00% | 0.0% |
| Q2 2020 | $760,000 | -89.6% | 15,680 | -91.0% | 0.00% | -91.7% |
| Q1 2020 | $7,339,000 | +4.3% | 173,700 | +5.6% | 0.02% | +33.3% |
| Q4 2019 | $7,037,000 | +18.9% | 164,500 | 0.0% | 0.02% | +12.5% |
| Q3 2019 | $5,920,000 | +34.6% | 164,500 | 0.0% | 0.02% | +33.3% |
| Q2 2019 | $4,397,000 | +20.3% | 164,500 | +20.9% | 0.01% | +20.0% |
| Q1 2019 | $3,654,000 | +123.5% | 136,100 | +34.6% | 0.01% | +100.0% |
| Q4 2018 | $1,635,000 | -22.7% | 101,100 | -0.8% | 0.01% | -16.7% |
| Q3 2018 | $2,115,000 | +35.9% | 101,900 | 0.0% | 0.01% | +50.0% |
| Q2 2018 | $1,556,000 | +252.0% | 101,900 | +417.8% | 0.00% | +300.0% |
| Q1 2018 | $442,000 | -27.5% | 19,679 | -2.9% | 0.00% | -50.0% |
| Q4 2017 | $610,000 | -17.6% | 20,261 | +3.1% | 0.00% | 0.0% |
| Q3 2017 | $740,000 | +38.8% | 19,655 | +2.8% | 0.00% | 0.0% |
| Q2 2017 | $533,000 | -30.3% | 19,112 | -14.1% | 0.00% | -33.3% |
| Q1 2017 | $765,000 | -52.0% | 22,252 | -59.7% | 0.00% | -57.1% |
| Q4 2016 | $1,593,000 | -21.9% | 55,226 | -13.9% | 0.01% | -12.5% |
| Q3 2016 | $2,040,000 | +1.3% | 64,140 | +3.4% | 0.01% | 0.0% |
| Q2 2016 | $2,014,000 | – | 62,040 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |